NasdaqCM:MLTXBiotechs
MoonLake Immunotherapeutics (MLTX) Q2 Net Loss Widens to US$55 Million
During the last quarter, MoonLake Immunotherapeutics (MLTX) reported a significant increase in net losses, with a net loss of $55 million for the second quarter, up from $24 million in the same period in 2024. This coincided with a broader market trend where tech stocks led the Nasdaq to record highs, and the S&P 500 saw growth. Despite the increase in losses, MoonLake's stock price rose by 19.02% over the quarter, moving in line with the overall market's upward trend of 19% over the past...